The Science Behind VERISORB™
Oral bioavailability is the unsolved problem in peptide delivery. Until now, the digestive tract's hostile environment destroyed peptide payloads before they ever reached your bloodstream.
The Bioavailability Gap
Standard oral delivery routes destroy up to 95% of delicate peptide molecules. VERISORB™ avoids the GI tract completely.
Standard Oral Capsules
Systemic Absorption
Payload is severely degraded by stomach acids and the hepatic first-pass effect.
VERISORB™ Sublingual
Higher Systemic Absorption*
Payload bypasses the digestive tract entirely, dissolving directly into the vascular sublingual mucosa.
*Preclinical animal data. Individual results may vary.
Precision engineered mucosal architecture.
Sublingual Absorption
The VERISORB™ tablet rests securely beneath the tongue, encountering a highly vascularized mucosal membrane. The peptide matrix dissolves in seconds without passing through the gastrointestinal tract.
Lipid Matrix Penetration
Pharmaceutical-grade lipid enhancers bind to the active peptide compounds. This temporarily expands the tight junctions of the oral mucosa, completely bypassing the hepatic first-pass effect.
Direct Bloodstream Entry
The payload deposits directly into the systemic circulation network via the sublingual artery. This rapid dissemination mirrors the bioavailability and efficacy of subcutaneous injection.
Pharmacokinetic markers mirroring subcutaneous injection.
Higher Preclinical Bioavailability
Preclinical animal data, 2024
Rapid Systemic Onset
Systemic marker clinical observation
Hepatic First-Pass
Established transmucosal mechanism
Bioavailability Data: Ivermectin PK/PD Study
| Delivery Method | Cmax (ng/mL) | AUC 0–24h | vs. Standard Oral |
|---|---|---|---|
| Quicksome Sublingual | 39.3 ± 10.4 | 435 ± 63.9 h·ng/mL | 7× better Cmax |
| Quicksol IM Injection | 11.0 ± 4.59 | 194 ± 94.1 h·ng/mL | 2.9× |
| Standard Oral Tablet | 5.60 ± 1.21 | 67.2 ± 20.0 h·ng/mL | Baseline |
Preclinical pharmacokinetic data. Beagle dog model, Ivermectin compound. Not human data. Not peptide-specific. Individual results may vary.
Clinical Evidence
The efficacy of VERISORB™ technology is backed by independent institutional validation and published biochemical science. All claims are supported by visible proof.
Quicksome™ Sublingual Pharmacokinetic Study
7× Cmax vs. standard oral
Sublingual liposomal delivery achieved 7× greater peak blood concentration versus standard oral tablet in preclinical research
* Preclinical animal data (beagle dogs). Ivermectin model. Not peptide-specific. Individual results may vary.
Read Source→FDA Laboratory Stability Validation — Quicksome™ Desiccated Liposomal Format
Stable at 40°C — independently verified
Quicksome™ desiccated liposomal technology demonstrated preservation of biological activity at elevated temperatures in partnership with an FDA laboratory
* Stability study conducted on Polio D Antigen. Validates delivery format stability, not peptide efficacy.
Read Source→Oral Peptide GI Degradation — Established Mechanism
Up to 95% GI degradation avoided via sublingual route
Standard oral peptide supplements are largely destroyed by digestive enzymes before reaching systemic circulation — up to 95% degradation documented in biochemical literature
* Mechanistic claim based on established peptide biochemistry. VERISORB™ bypasses this mechanism via sublingual mucosal absorption.
Read Source→